Mineralocorticoid receptor antagonist for renal protection

Renal Failure

Volumn 34, Issue 6, 2012, Pages 810-817

  Ma, Terry King Wing ^a   Szeto, Cheuk Chun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

chronic kidney disease; hypertension; proteinuria

Indexed keywords

ALDOSTERONE; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; RAMIPRIL; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; GYNECOMASTIA; HORMONE ACTION; HUMAN; HYPERKALEMIA; MACROALBUMINURIA; MENSTRUAL IRREGULARITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR AFFINITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; KIDNEY DISEASES; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 84862215954     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.672156     Document Type: Review

References (48)

1. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 2010;160:1273-1292.
2. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(Suppl. 2):S12-S154.
3. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8-20.
4. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
5. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372:547-553.
6. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1-9. (Pubitemid 38870076)
7. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697. (Pubitemid 33126826)
8. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 1982;49:1561-1563. (Pubitemid 12060503)
9. Balcells E, Meng QC, Johnson Jr WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol. 1997;273(4 Pt 2):H1769-H1774.
10. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364-2372. (Pubitemid 36724399)
11. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159-172.
12. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068. (Pubitemid 26293326)
13. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209-F220. (Pubitemid 34778983)
14. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 2006;70:1914-1919. (Pubitemid 44863378)
15. Shah SV. Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int. 1989;35:1093-1106. (Pubitemid 19167894)
16. Ruiz-Ortega M, Rupérez M, Esteban V, et al. Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant. 2006;21:16-20. (Pubitemid 43057101)
17. Lai L, Pen A, Hu Y, et al. Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. Life Sci. 2007;81:570-576. (Pubitemid 47212237)
18. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73.
19. Xavier FE, Aras-López R, Arroyo-Villa I, et al. Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol. 2008;154: 1225-1235. (Pubitemid 351992068)
20. +-adenosine triphosphatase in arterial vessels. Endocrinology. 2003;144:1266-1272.
21. Wehling M, Ulsenheimer A, Schneider M, Neylon C, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: Subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun. 1994;204:475-481.
22. Wehling M, Bauer MM, Ulsenheimer A, Schneider M, Neylon CB, Christ M. Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun. 1996;223:181-186. (Pubitemid 26202497)
23. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: Involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995;213:123-129.
24. Funder JW. Aldosterone and mineralocorticoid receptors: Orphan questions. Kidney Int. 2000;57:1358-1363. (Pubitemid 30207891)
25. Rafiq K, Nakano D, Ihara G, et al. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens. 2011;29:290-298.
26. Shibata S, Fujita T. The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep. 2011;13:109-115.
27. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis. 2008;51:199-211.
28. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106-2112. (Pubitemid 41242452)
29. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285-2292. (Pubitemid 44611039)
30. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829-2836. (Pubitemid 43251030)
31. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-542. (Pubitemid 44141580)
32. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926.
33. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of reninangiotensin- aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59-67. (Pubitemid 351325616)
34. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486-493.
35. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116-2123. (Pubitemid 44871374)
36. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951.
37. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One. 2011;6:e26904.
38. Ando K, Ohtsu H, Arakawa Y, et al. Rationale and design of the eplerenone combination versus conventional agents to lower blood pressure on urinary antialbuminuric treatment effect (EVALUATE) trial. Hypertens Res. 2010;33:616-621.
39. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084-1093. (Pubitemid 44289165)
40. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension. 2007;49:355-364.
41. Whaley-Connell A, Habibi J, Wei Y, et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2009;296:F1013-F1022.
42. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2009;3:CD007004.
43. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;4:CD006257.
44. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.NEngl J Med. 1999;341:709-717. (Pubitemid 29407370)
45. Juurlink DN, MamdaniMM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551. (Pubitemid 39025171)
46. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418-424.
47. Pitt B, Remme W, Zannad F, et al. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.NEngl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
48. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2006;20:2641-2650.